HomeCompareFREQ vs BTI

FREQ vs BTI: Dividend Comparison 2026

FREQ yields 667.56% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 FREQ wins by $614802.02M in total portfolio value
10 years
FREQ
FREQ
● Live price
667.56%
Share price
$0.30
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$614802.06M
Annual income
$474,868,230,549.69
Full FREQ calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — FREQ vs BTI

📍 FREQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFREQBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FREQ + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FREQ pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FREQ
Annual income on $10K today (after 15% tax)
$56,742.32/yr
After 10yr DRIP, annual income (after tax)
$403,637,995,967.24/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, FREQ beats the other by $403,637,993,598.59/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FREQ + BTI for your $10,000?

FREQ: 50%BTI: 50%
100% BTI50/50100% FREQ
Portfolio after 10yr
$307401.05M
Annual income
$237,434,116,668.17/yr
Blended yield
77.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

FREQ
Analyst Ratings
3
Buy
4
Hold
Consensus: Hold
Price Target
$1.40
+367.3% upside vs current
Range: $1.40 — $1.40
Altman Z
-7.4
Piotroski
3/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FREQ buys
0
BTI buys
0
No recent congressional trades found for FREQ or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFREQBTI
Forward yield667.56%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$614802.06M$37.7K
Annual income after 10y$474,868,230,549.69$2,786.64
Total dividends collected$603369.48M$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy
Analyst price target$1.40$40.00

Year-by-year: FREQ vs BTI ($10,000, DRIP)

YearFREQ PortfolioFREQ Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$77,456$66,755.67$11,299$598.92+$66.2KFREQ
2$566,112$483,234.18$12,794$703.91+$553.3KFREQ
3$3,906,567$3,300,827.31$14,518$829.07+$3.89MFREQ
4$25,467,892$21,287,865.51$16,513$978.64+$25.45MFREQ
5$156,952,466$129,701,821.96$18,827$1,157.84+$156.93MFREQ
6$914,968,107$747,028,968.25$21,518$1,373.12+$914.95MFREQ
7$5,048,988,394$4,069,972,519.36$24,657$1,632.46+$5048.96MFREQ
8$26,392,111,970$20,989,694,387.90$28,329$1,945.74+$26392.08MFREQ
9$130,779,275,796$102,539,715,988.68$32,637$2,325.33+$130779.24MFREQ
10$614,802,055,652$474,868,230,549.69$37,708$2,786.64+$614802.02MFREQ

FREQ vs BTI: Complete Analysis 2026

FREQStock

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Full FREQ Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this FREQ vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FREQ vs SCHDFREQ vs JEPIFREQ vs OFREQ vs KOFREQ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.